Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Change in Accured Expenses (2021 - 2026)

HeartSciences (HSCS) has disclosed Change in Accured Expenses for 5 consecutive years, with -$334208.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 55.04% year-over-year to -$334208.0, compared with a TTM value of $109573.0 through Oct 2025, up 139.02%, and an annual FY2025 reading of $16791.0, up 128.61% over the prior year.
  • Change in Accured Expenses was -$334208.0 for Q4 2025 at HeartSciences, down from $166718.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $371484.0 in Q2 2022 and bottomed at -$477475.0 in Q3 2022.
  • Average Change in Accured Expenses over 5 years is $19211.6, with a median of $21737.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses tumbled 997.02% in 2022, then skyrocketed 472.92% in 2025.
  • Year by year, Change in Accured Expenses stood at $144380.0 in 2021, then skyrocketed by 71.17% to $247141.0 in 2022, then plummeted by 126.67% to -$65901.0 in 2023, then tumbled by 227.11% to -$215566.0 in 2024, then tumbled by 55.04% to -$334208.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for HSCS at -$334208.0 in Q4 2025, $166718.0 in Q3 2025, and $261319.0 in Q2 2025.